Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
RSV OR THE FLU? NOW YOU KNOW IT IMMEDIATELY

Janssen Diagnostics has developed a molecular diagnostic test which will be used with the Biocartis’ Idylla™ platform, to determine Influenza and …


Ebola diagnostics – faster, safer, and more accurate

“Last year the Ebola outbreak kick-started the development of a fast and accurate Ebola test to be used with Biocartis’ Idylla™ platform” - says D…


Watch out for Lyme disease!

Summer is coming, it’s getting warmer, and you’re planning on outdoor activities. Unfortunately, ticks are getting out there as well, and your cha…

POPULAR TAGS

Biocartis’ Ebola test approved for emergency use

Written by LVS on in the category news with the tags , .


The U.S. Food and Drug Administration (FDA) has granted Biocartis’ Ebola Virus Triage Test emergency use authorization. The test was developed in collaboration with Janssen Diagnostics and the Institute of Tropical Medicine, which also discovered the virus 40 years ago.

The Ebola detection assay is remarkably simple: a blood sample of a suspected patient is added to the detection cartridge, which is then inserted into Biocartis’ diagnostic platform Idylla™. Within roughly an hour and a half, the test provides accurate results. The cartridges are hermetically sealed after addition of the sample, limiting healthcare worker exposure to the virus, and no specially trained lab personnel is needed to carry out the test. Idylla’s compactness also make is very suitable for use in remote locations.

The Ebola outbreak of 2014 was the largest ever, and although the worst of the outbreak has passed, experts expect sporadic flare-ups and possible outbreaks of Ebola in the future.

Rudi Pauwels, Biocartis CEO, commented: "The 2014 Ebola and more recently the Zika outbreak, demonstrates that in today's global world we need rapid, highly accurate and easily deployable diagnostic systems. The Idylla™ Ebola Virus Triage Test is the first infectious disease outbreak test authorized by the FDA on our Idylla™ platform, which is - thanks to its unique features - perfectly suited for outbreak control through early and fast testing. The test allows healthcare professionals in the field to rapidly diagnose infection, implement control measures and as such, open doors to faster and better treatment decisions."

Read more about: , .

RELATED ARTICLES
RSV OR THE FLU? NOW YOU KNOW IT IMMEDIATELY

Janssen Diagnostics has developed a molecular diagnostic test which will be used with the Biocartis’ Idylla™ platform, to determine Influenza and …


Ebola diagnostics – faster, safer, and more accurate

“Last year the Ebola outbreak kick-started the development of a fast and accurate Ebola test to be used with Biocartis’ Idylla™ platform” - says D…


Watch out for Lyme disease!

Summer is coming, it’s getting warmer, and you’re planning on outdoor activities. Unfortunately, ticks are getting out there as well, and your cha…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Janssen Flanders.bio Biowin KU Leuven UGent GSK V-Bio Ventures XpandInnovation Itera Life Science Turnstone

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.